Freedom Broker has raised its target price for Viemed Healthcare, a smaller company that provides in-home respiratory support, by more than 18% to $11 per share. The upgrade is attributable to the company’s third-quarter financial results, which beat expectations amid robust demand in the sleep therapy segment. Viemed links this growth to the rising popularity of weight-loss drugs.

Freedom Broker raises Viemed target price amid growing sleep therapy market

Small caps might not have much further to run in the postelection rally, as they are at risk from higher interest rates, <a href="https://www.marketwatch.com/story/the-post-election-rally-should-continue-except-this-one-part-says-morgan-stanleys-mike-wilson-bfc49971?mod=bulletin_ribbon&amp;utm_source=in_materials">warns</a> Morgan Stanley’s chief U.S. equities strategist Mike Wilson. He recalls that after Donald Trump’s previous election win in 2016, their relative performance peaked in early December.

Morgan Stanley: Postelection rally to continue, but without small caps

Archer Aviation, an electric vertical takeoff and landing (eVTOL) aircraft manufacturer, is one of the small-cap stocks that could benefit from the incoming administration of Donald Trump, according to Freedom Broker. Its analysts have set a target price of $4.80 per share for Archer, implying 23% upside versus the last closing price.

Freedom Broker spotlights Archer Aviation as small cap poised to rally on Trump win

Equillium, a biotech company developing treatments for severe autoimmune diseases, saw its stock price <a href="https://www.marketwatch.com/investing/stock/eq?utm_source=in_materials">plummet</a> almost 38% on Thursday, October 31. The sharp drop followed <a href="https://www.equilliumbio.com/investors/press-releases/news-details/2024/Equillium-Maintains-Rights-to-Itolizumab-Following-Ono-Partnership/default.aspx?utm_source=in_materials">news</a> that Japan’s Ono Pharmaceutical had opted not to exercise its option to purchase rights to Equillium’s experimental drug for organ transplant rejection. In early trading today, Friday, November 1, Equillium shares continued to slide, down another 2.5% as of this writing.

Biotech firm Equillium loses third of market value in a day after Ono no-go

Shares of MAIA Biotechnology, a company with a market capitalization of $65 million that develops therapies for cancer, <a href="https://www.marketwatch.com/investing/stock/maia?utm_source=in_materials">surged</a> more than 8% on Tuesday, October 29, following the <a href="https://ir.maiabiotech.com/news-events/press-releases/detail/115/maia-biotechnology-announces-2-44-million-private-placement?utm_source=in_materials">announcement</a> of a private placement, which included certain insiders and is expected to raise $2.44 million.

Oncology company MAIA advances on news of private placement

ImmunityBio, a biotech company developing novel cancer treatments, has been valued at $30 per share in a coverage initiation <a href="https://www.barrons.com/articles/biotech-stock-price-immunitybio-84ca43e9?mod=RTA">report</a> by EF Hutton, an investment bank. Recall that EF Hutton was known as one of the top banks for SPAC deals, including Donald Trump's Trump Media &amp; Technology Group. The bank’s target price for ImmunityBio is more than seven times the October 24 close of $4.20 per share.

EF Hutton sees over 600% upside in biotech small cap ImmunityBio

The journey of Achieve Life Sciences, a small pharmaceutical company, is a case study in persistence. Over its 33-year history, it has faced multiple clinical trial setbacks, launched just a single product (with limited commercial success), and shifted its focus and branding more than once. Today, Achieve is developing the world’s first treatment specifically for vaping addiction, which recently received "breakthrough therapy" designation from the U.S. Food and Drug Administration (FDA).

Third time’s the charm: How Achieve Life Sciences developed a breakthrough drug for vaping addiction

"In my entire life, I never dreamed that we would be talking about medicines that are providing hope for people like me who have struggled for years with being overweight or with obesity," famous TV host Oprah Winfrey <a href="https://people.com/celebrities-ozempic-wegovy-what-theyve-said-7104926">told</a> magazine two and a half years after Novo Nordisk's weight-loss drug Wegovy hit the market. Currently, Wegovy and Zepbound, made by U.S.-based Eli Lilly, account for 95% of the obesity market. In the upcoming years, however, they may face over a dozen new competitors. Which companies should investors keep an eye on in the space?

The skinny on investing in the weight-loss drug market

Wall Street offers plenty of small-cap investment ideas, but not all smaller firms are profit-making, and the chances of such investments paying off big or going to zero are about equal, notes market research site Simply Wall St. Georgiy Timoshin, a financial analyst at Freedom Finance Global, highlights two currently-unprofitable small-cap companies that may appeal to investors with a high tolerance for risk.

Freedom Finance analyst highlights two small caps for risk-tolerant investors

Shares of Freedom Holding have gained about 600% since listing five years ago on the Nasdaq. In 2019, the company became the first broker from the CIS on this U.S. exchange. Indeed, the Nasdaq IPO gave the business a major boost, says CEO Timur Turlov.

Freedom Holding skyrockets 600% in five years on Nasdaq

For high returns, investors should <a href="https://kz.kursiv.media/2024-09-19/mrdr-smallcaps-2/">look for</a> small-cap investments with the potential to grow into the mid-cap or even large-cap segment. Georgiy Timoshin, a financial analyst at Freedom Finance Global, highlights two undervalued companies that he believes could do just that.

Freedom Finance analyst spotlights two small caps with big potential

Small caps turned out to be some of the most profitable investments in the third quarter of 2024. The iShares Russell 2000 ETF (which tracks the performance of the Russell 2000 index) reported an 8.87% return versus 5.43% for the large-cap S&amp;P 500, points out Georgiy Timoshin, a financial analyst at Freedom Finance Global. He has spotlighted five stocks from the Russell 2000 that delivered third-quarter returns of over 100%.